Ocular surface toxicities associated with modern anticancer therapies

Immune checkpoint receptors in autoimmunity

(2023) Kelly P Burke et al.   CURRENT OPINION IN IMMUNOLOGY

A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?

(2023) Jingyang Su et al.   CURRENT OPINION IN ONCOLOGY

Immunotherapies in rare cancers

(2023) Sneha Vivekanandhan et al.   Molecular Cancer

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

(2023) Lipika Goyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges

(2023) Petros Moustardas et al.   Cells

Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor

(2022) Benjamin Chin-Yee et al.   ANNALS OF HEMATOLOGY

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

(2022) A. Gazzah et al.   ANNALS OF ONCOLOGY

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

(2022) Katrin Haeussler et al.   Future Oncology

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice

(2022) M. Villagrán-García et al.   NEUROLOGICAL SCIENCES

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Marginal corneal infiltration following treatment for metastatic breast cancer with triple chemotherapy of Trastuzumab, Pertuzumab & Docetaxel

(2022) Ghyath Kafa et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

(2022) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Mitigation and management strategies for ocular events associated with tisotumab vedotin

(2022) Stella K. Kim et al.   GYNECOLOGIC ONCOLOGY

Bilateral periorbital, eyelid, and conjunctival edema and hair color changes caused by avapritinib

(2022) N. Padrón-Pérez   JOURNAL FRANCAIS D OPHTALMOLOGIE

Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2022) Maria S. Asdourian et al.   JAMA Dermatology

Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging

(2022) Rita Mencucci et al.   Journal of Clinical Medicine

Targeted therapy for breast cancer: An overview of drug classes and outcomes

(2022) Aaron T. Jacobs et al.   BIOCHEMICAL PHARMACOLOGY

Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events

(2022) Stinne R. Greisen et al.   Frontiers in Immunology

Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experience

(2022) Meera Mohan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Corneal Toxicity Associated With Belantamab Mafodotin Is Not Restricted to the Epithelium: Neuropathy Studied With Confocal Microscopy

(2022) Julia Aschauer et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress)

(2022) T. André et al.   ANNALS OF ONCOLOGY

Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma

(2022) Kenta Nakamura et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Associations between ocular and extra-ocular assessment in primary Sjögren's syndrome*

(2022) Elodie Da Cunha et al.   JOINT BONE SPINE

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases

(2022) Alice Tison et al.   Nature Reviews Rheumatology

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

(2022) Junjie Liu et al.   Frontiers in Immunology

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

(2022) Olivier J. van Not et al.   JAMA Oncology

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors

(2022) Majid Moshirfar et al.   Journal of Clinical Medicine

Ocular Inflammation Induced by Immune Checkpoint Inhibitors

(2022) Florence Chaudot et al.   Journal of Clinical Medicine

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary

(2022) Annamaria Mascolo et al.   Frontiers in Cardiovascular Medicine

Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management

(2022) Kai R. Plunkett et al.   Frontiers in Immunology

A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer

(2022) Deborah Peeters et al.   Case Reports in Ophthalmology

The management of metastatic GIST: current standard and investigational therapeutics

(2021) Ciara M. Kelly et al.   Journal of Hematology & Oncology

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

(2021) K.N. Moore et al.   ANNALS OF ONCOLOGY

Reversible HER2 antibody-drug conjugate–induced ocular toxicity

(2021) Anushree Sharma et al.   CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE

Perforation cornéenne sous chimiothérapie inhibiteur des tyrosines kinases : REGORAFENIB

(2021) L. Lanfant et al.   JOURNAL FRANCAIS D OPHTALMOLOGIE

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

(2021) Martine Piccart et al.   JOURNAL OF CLINICAL ONCOLOGY

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

(2021) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

(2021) Robert Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma

(2021) Dimitrios C. Ziogas et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Gastrointestinal stromal tumor: a review of current and emerging therapies

(2021) Bayan Al-Share et al.   CANCER AND METASTASIS REVIEWS

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study

(2021) H. M. Stege et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Next generation of immune checkpoint inhibitors and beyond

(2021) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

(2021) Robert L Coleman et al.   LANCET ONCOLOGY

Antibody–Drug Conjugates—A Tutorial Review

(2021) Stephanie Baah et al.   MOLECULES

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocular surface disease associated with immune checkpoint inhibitor therapy

(2021) Royce B. Park et al.   Ocular Surface

Overview of Ocular Side Effects of Selinexor

(2021) Nagham Al‐Zubidi et al.   ONCOLOGIST

Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization Pharmacovigilance Database

(2021) Camille Mettler et al.   OPHTHALMOLOGY

Tumors, tumor therapies, autoimmunity and the eye

(2021) Gerhild Wildner   AUTOIMMUNITY REVIEWS

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

(2021) Yoon-Koo Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Corneal Epitheliopathy Associated With Antibody-Drug Conjugates

(2021) Sanjay V. Patel et al.   MAYO CLINIC PROCEEDINGS

FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

(2021) Yvette L. Kasamon et al.   ONCOLOGIST

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

(2021) Funda Meric-Bernstam et al.   Cancer Discovery

Epidermal Growth Factor Receptor Expression in the Corneal Epithelium

(2021) Joanne L. Peterson et al.   Cells

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

(2021) Golnaz Morad et al.   CELL

Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates

(2021) Julia Canestraro et al.   CORNEA

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial

(2021) Ye Guo et al.   EUROPEAN JOURNAL OF CANCER

Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report

(2021) Kevin Marquant et al.   Journal of Hematology & Oncology

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

(2021) Jason Gotlib et al.   NATURE MEDICINE

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

(2021) Hervé Tilly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in systemic therapy for non-small cell lung cancer

(2021) Meagan Miller et al.   BMJ-British Medical Journal

Advances in acute myeloid leukemia

(2021) Laura F Newell et al.   BMJ-British Medical Journal

Evolving role of regorafenib for the treatment of advanced cancers

(2020) Axel Grothey et al.   CANCER TREATMENT REVIEWS

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines

(2020) Takuji Okusaka et al.   JOURNAL OF GASTROENTEROLOGY

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

(2020) Eunhae Shin et al.   BMC Ophthalmology

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

(2020) Ufuk Degirmenci et al.   Cells

The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

(2020) Jean-Marie Michot et al.   EUROPEAN JOURNAL OF CANCER

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

(2020) Yelena Y Janjigian et al.   LANCET ONCOLOGY

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors

(2020) R. Bahleda et al.   ANNALS OF ONCOLOGY

Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors

(2020) Junko Hori et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

XPO1-dependent nuclear export as a target for cancer therapy

(2020) Nancy G. Azizian et al.   Journal of Hematology & Oncology

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

(2020) Michael C Heinrich et al.   LANCET ONCOLOGY

Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis

(2020) David Bomze et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

(2020) Ilaria Proietti et al.   Cancers

Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience

(2020) Blake Hugo Fortes et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Nivolumab-Induced Ulcerative Keratitis—A Case Report

(2020) Gergely Losonczy et al.   CORNEA

Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy

(2020) Anaïs Ramaekers et al.   CORNEA

Belantamab Mafodotin: First Approval

(2020) Anthony Markham   DRUGS

Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness

(2020) Harpal Singh Sandhu et al.   Immunotherapy

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

(2020) Paul G. Richardson et al.   Blood Cancer Journal

Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients

(2020) Rebecca B. Bausell et al.   Eye & Contact Lens-Science and Clinical Practice

Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery

(2020) Antoine Rousseau et al.   OPHTHALMOLOGY

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

(2020) Hyun Cheol Chung et al.   Future Oncology

Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry

(2020) Michel M. Sun et al.   OPHTHALMOLOGY

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

(2019) Johann S de Bono et al.   LANCET ONCOLOGY

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

(2019) Michael J Birrer et al.   JNCI-Journal of the National Cancer Institute

Corneal features in trastuzumab emtansine treatment: not a rare occurrence

(2019) Els Deklerck et al.   BREAST CANCER RESEARCH AND TREATMENT

Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy

(2019) Karen Bitton et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

(2019) Blake M. Warner et al.   ONCOLOGIST

Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates

(2019) Prathap Kumar Mahalingaiah et al.   PHARMACOLOGY & THERAPEUTICS

Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series

(2019) Bonnie A. Sklar et al.   BMC Ophthalmology

Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib

(2019) Abbas Khokar et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

(2019) Lara E. Davis et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

(2019) Kazutoshi Komiya et al.   Thoracic Cancer

Selinexor: First Global Approval

(2019) Yahiya Y. Syed   DRUGS

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

Distichiasis in association with entropion in metastatic HER2‐positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy

(2019) Faruk Tas et al.   Breast Journal

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Corneal Changes in Trastuzumab Emtansine Treatment

(2018) Elke O. Kreps et al.   Clinical Breast Cancer

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

(2018) Mario E. Lacouture et al.   Clinical Colorectal Cancer

Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma

(2018) Pedro Arriola-Villalobos et al.   CORNEA

A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

(2018) Marek Trněný et al.   HAEMATOLOGICA

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

(2018) Qinlian Jiao et al.   Molecular Cancer

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

(2018) Marek Trněný et al.   HAEMATOLOGICA

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

(2018) Ursula A Matulonis et al.   CLINICAL CANCER RESEARCH

Ocular Toxicity of Mirvetuximab

(2018) Eleonora Corbelli et al.   CORNEA

Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1

(2017) H-B Qiu et al.   PHARMACOGENOMICS JOURNAL

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract

(2017) Michael Dougan   Frontiers in Immunology

Trichomegaly Induced by Cetuximab

(2016) Ulkuhan I. Koksal et al.   AMERICAN JOURNAL OF THERAPEUTICS

Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis

(2016) Marie-Charlotte Veys et al.   Clinical Lymphoma Myeloma & Leukemia

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Cyclosporine for Dry Eye Associated With Nivolumab

(2016) Alexander T. Nguyen et al.   CORNEA

Association Between Bortezomib Therapy and Eyelid Chalazia

(2016) Frederick W. Fraunfelder et al.   JAMA Ophthalmology

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report

(2015) A. Orlandi et al.   BMC CANCER

Effets indésirables oculaires des traitements systémiques : une mise à jour

(2015) A. Rousseau et al.   JOURNAL FRANCAIS D OPHTALMOLOGIE

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

(2015) Joshua Seth Eaton et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer

(2014) J. M. Drake et al.   MOLECULAR AND CELLULAR BIOLOGY

Chalazia Associated with Bortezomib Therapy for Multiple Myeloma

(2014) Seanna R. Grob et al.   OPHTHALMOLOGY

Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy

(2014) Wajiha J. Kheir et al.   SURVEY OF OPHTHALMOLOGY

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

(2013) Grace K. Dy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

EGF receptor trafficking: consequences for signaling and cancer

(2013) Alejandra Tomas et al.   TRENDS IN CELL BIOLOGY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review

(2012) Durga S. Borkar et al.   SUPPORTIVE CARE IN CANCER

Trichomegaly and other external eye side effects associated with epidermal growth factor

(2011) Frederick T. Fraunfelder et al.   Cutaneous and Ocular Toxicology

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL